Event

Aryeh Fischer

M.D.
Univ of Colorado Denver;University of Colorado School of Medicine

Leila Zouad-Lejour

MSc
Boehringer Ingelheim Pharma GmbH & Co. KG

Baher Mounir

B Pharm
Boehringer Ingelheim Pharma GmbH & Co. KG

Marlies Wijsenbeek

MD, PhD
Erasmus MC, University Medical Centre;Erasmus Medical Center;Erasmus University Medical Center

Christopher D. Wells

PhD
Decision Resources Group

Elisabeth Bendstrup

MD, PhD
Aarhaus University;Aarhus University Hospital

Michael Kreuter

MD, PhD
Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Thoraxklin;Center for interstitial and rare lung diseases, Pneumology, Thoraxklinik, University of Heidelberg,

Amy L. Olson

MD, MSPH
National Jewish Health

Manuel Quaresma

PharmD
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, and Center for Interstitial and Rare ;Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, and Center for Interstitial

Current Treatment of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease